NewAmsterdam Pharma Company N.V (NAMS)

Key Updates

NAMS has recovered 3.88% since the September 22 report, rising from approximately $22.58 to $23.45, extending a stabilization phase after the sharp declines recorded in early-to-mid September. No new company-specific news was reported during this period (0 articles), indicating the recent price recovery is likely driven by technical factors, broader market sentiment, or short-covering rather than fundamental catalysts. Despite this short-term uptick, the stock remains deeply negative on a YTD basis (-33.14%) and has not recovered the ground lost over the 1-month (-9.44%) and 6-month (-21.76%) horizons.

Current Trend

NAMS continues to trade within a broader downtrend that has persisted throughout 2026. Key observations:

• YTD performance remains sharply negative at -33.14%, reflecting sustained selling pressure over the year.
• The 6-month decline of -21.76% confirms the downtrend has been consistent, not merely a recent event.
• Short-term price action shows tentative stabilization: +0.58% over 5 days and +3.88% since the last report, suggesting a potential near-term basing pattern following the September 9-10 capitulation (-10.06% and -10.08% moves).
• The absence of fresh news accompanying this recovery raises questions about its sustainability, as it appears unsupported by fundamental developments.

Investment Thesis

The investment thesis for NAMS remains centered on its pipeline execution and cash runway as a clinical/commercial-stage pharmaceutical company. Absent new catalysts in this reporting period, the core thesis drivers identified in prior reports remain unchanged:

• Company-specific: pipeline progress, regulatory milestones, and cash position remain the primary value drivers.
• Market-wide: broader biotech sector sentiment and risk appetite for clinical-stage names continue to influence price action, particularly given the lack of idiosyncratic news flow.

Thesis Status

The thesis status remains cautious and largely unchanged from the prior two reports. The stock has not demonstrated a fundamental turnaround; rather, the current bounce appears technical in nature given the absence of supporting news. The magnitude of the YTD decline (-33.14%) indicates that whatever thesis supported earlier valuations has been substantially challenged by sustained multi-month selling pressure. Investors should treat the recent +3.88% move as a potential relief rally within a downtrend rather than confirmation of a reversal until corroborated by fundamental news or a sustained break of recent resistance levels.

Key Drivers

No new news events were reported in this period, which is itself a notable data point. With 0 articles driving the +3.88% price change, the movement is attributed to price-driven technical dynamics rather than fundamental developments. This contrasts with the pattern of prior reports (September 9 and September 10), where large negative moves also occurred without fresh news, suggesting the stock has been highly sensitive to market-wide or sector-wide sentiment shifts rather than company-specific announcements in recent weeks.

Technical Analysis

NAMS is currently priced at $23.45, having recovered from the September 22 level of $22.58. Key technical observations:

• Short-term support appears to have formed near the $21.86 level established on September 10, which has held through the subsequent price action.
• The stock faces resistance around the $24.31 level seen on September 9, prior to the sharp single-day -5.15% decline.
• The 5-day change of +0.58% combined with the +3.88% move since the last report suggests building near-term momentum, though this remains well within the context of a longer-term downtrend (-21.76% over 6 months).
• A sustained move above the $24.31 resistance zone would be a more constructive technical signal; failure to hold above $21.86 support would reaffirm bearish continuation risk.

Bull Case

• Price has stabilized and recovered +3.88% since the last report and +0.58% over 5 days, suggesting the September capitulation lows ($21.86) may be holding as near-term support.
• The magnitude of the prior declines (-10.06% and -10.08% in consecutive reports) may have priced in significant negative sentiment, potentially setting up for a technical mean-reversion bounce.
• Absence of negative news during the recovery period suggests the prior sell-off was not driven by a deteriorating fundamental outlook, which could support price stabilization.
• A successful break above the $24.31 resistance level (September 9 pre-decline price) could signal the beginning of a technical trend reversal.
• The current price of $23.45 remains above the September 10 trough of $21.86, indicating the immediate downside momentum has decelerated.

Bear Case

• YTD performance remains deeply negative at -33.14%, reflecting a sustained and severe deterioration in market valuation over the year that has not been offset by recent stabilization.
• The 6-month decline of -21.76% indicates the downtrend is structural rather than a short-term aberration, raising concerns about the durability of the current bounce.
• The stock has previously experienced repeated large negative moves without corresponding news catalysts (-10.06% on September 9, -10.08% on September 10), suggesting elevated volatility and vulnerability to further sharp declines.
• The current recovery is unsupported by any new fundamental catalysts (0 news articles), making it difficult to distinguish a genuine reversal from a temporary technical bounce within a broader downtrend.
• The 1-month performance remains negative at -9.44% despite the recent 5-day uptick, indicating the medium-term trend has not yet turned positive.